Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice.

Willis E, Pardi N, Parkhouse K, Mui BL, Tam YK, Weissman D, Hensley SE.

Sci Transl Med. 2020 Jan 8;12(525). pii: eaav5701. doi: 10.1126/scitranslmed.aav5701.

PMID:
31915303
2.

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.

Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR.

Nat Nanotechnol. 2019 Dec;14(12):1084-1087. doi: 10.1038/s41565-019-0591-y. No abstract available.

PMID:
31802031
3.

Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin.

Huysmans H, Zhong Z, De Temmerman J, Mui BL, Tam YK, Mc Cafferty S, Gitsels A, Vanrompay D, Sanders NN.

Mol Ther Nucleic Acids. 2019 Sep 6;17:867-878. doi: 10.1016/j.omtn.2019.08.001. Epub 2019 Aug 7.

4.

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques.

Pardi N, LaBranche CC, Ferrari G, Cain DW, Tombácz I, Parks RJ, Muramatsu H, Mui BL, Tam YK, Karikó K, Polacino P, Barbosa CJ, Madden TD, Hope MJ, Haynes BF, Montefiori DC, Hu SL, Weissman D.

Mol Ther Nucleic Acids. 2019 Apr 15;15:36-47. doi: 10.1016/j.omtn.2019.03.003. Epub 2019 Mar 21.

5.

Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets.

Conway A, Mendel M, Kim K, McGovern K, Boyko A, Zhang L, Miller JC, DeKelver RC, Paschon DE, Mui BL, Lin PJC, Tam YK, Barbosa C, Redelmeier T, Holmes MC, Lee G.

Mol Ther. 2019 Apr 10;27(4):866-877. doi: 10.1016/j.ymthe.2019.03.003. Epub 2019 Mar 7.

PMID:
30902585
6.

PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake.

Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, Uhler T, Tuyishime S, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D, Muzykantov VR.

J Control Release. 2018 Dec 10;291:106-115. doi: 10.1016/j.jconrel.2018.10.015. Epub 2018 Oct 15.

7.

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.

Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D.

Nat Commun. 2018 Aug 22;9(1):3361. doi: 10.1038/s41467-018-05482-0.

8.

Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids.

Chen S, Zaifman J, Kulkarni JA, Zhigaltsev IV, Tam YK, Ciufolini MA, Tam YYC, Cullis PR.

J Control Release. 2018 Sep 28;286:46-54. doi: 10.1016/j.jconrel.2018.07.026. Epub 2018 Jul 17.

PMID:
30026080
9.

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D.

J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8.

10.

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.

Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, Tam YK, Madden TD, Hope MJ, Heidenreich R, Fotin-Mleczek M.

NPJ Vaccines. 2017 Oct 19;2:29. doi: 10.1038/s41541-017-0032-6. eCollection 2017.

11.

Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles.

Kulkarni JA, Tam YYC, Chen S, Tam YK, Zaifman J, Cullis PR, Biswas S.

Nanoscale. 2017 Sep 21;9(36):13600-13609. doi: 10.1039/c7nr03272b.

PMID:
28876010
12.

mRNA mediates passive vaccination against infectious agents, toxins, and tumors.

Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, Fotin-Mleczek M, Shoemaker CB, Schlake T.

EMBO Mol Med. 2017 Oct;9(10):1434-1447. doi: 10.15252/emmm.201707678.

13.

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.

Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, Shaheen F, Collman RG, Karikó K, Danet-Desnoyers GA, Madden TD, Hope MJ, Weissman D.

Nat Commun. 2017 Mar 2;8:14630. doi: 10.1038/ncomms14630.

14.

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D.

Nature. 2017 Mar 9;543(7644):248-251. doi: 10.1038/nature21428. Epub 2017 Feb 2.

15.

A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo.

Lee JB, Zhang K, Tam YY, Quick J, Tam YK, Lin PJ, Chen S, Liu Y, Nair JK, Zlatev I, Rajeev KG, Manoharan M, Rennie PS, Cullis PR.

Mol Ther Nucleic Acids. 2016;5:e348. doi: 10.1038/mtna.2016.43.

16.

Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA?

Tam YK, Madden TD, Hope MJ.

J Drug Target. 2016 Nov;24(9):774-779. Epub 2016 Sep 2. Review.

PMID:
27588674
17.

Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.

Chen S, Tam YYC, Lin PJC, Sung MMH, Tam YK, Cullis PR.

J Control Release. 2016 Aug 10;235:236-244. doi: 10.1016/j.jconrel.2016.05.059. Epub 2016 May 26.

PMID:
27238441
18.

Evaluation of the bioavailability of major withanolides of Withania somnifera using an in vitro absorption model system.

Devkar ST, Kandhare AD, Sloley BD, Jagtap SD, Lin J, Tam YK, Katyare SS, Bodhankar SL, Hegde MV.

J Adv Pharm Technol Res. 2015 Oct-Dec;6(4):159-64. doi: 10.4103/2231-4040.165023.

19.

Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.

Lin PJ, Tam YK.

Future Med Chem. 2015;7(13):1751-69. doi: 10.4155/fmc.15.108. Epub 2015 Sep 24. Review.

PMID:
26399560
20.

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D.

J Control Release. 2015 Nov 10;217:345-51. doi: 10.1016/j.jconrel.2015.08.007. Epub 2015 Aug 8.

21.

Production of limit size nanoliposomal systems with potential utility as ultra-small drug delivery agents.

Zhigaltsev IV, Tam YK, Leung AK, Cullis PR.

J Liposome Res. 2016;26(2):96-102. doi: 10.3109/08982104.2015.1025411. Epub 2015 Apr 9.

PMID:
25856305
22.

Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.

Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, Cullis PR.

J Control Release. 2014 Dec 28;196:106-12. doi: 10.1016/j.jconrel.2014.09.025. Epub 2014 Oct 5.

PMID:
25285610
23.

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.

Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, Lin PJ, Chen S, Narayanannair JK, Rajeev KG, Manoharan M, Akinc A, Maier MA, Cullis P, Madden TD, Hope MJ.

Mol Ther Nucleic Acids. 2013 Dec 17;2:e139. doi: 10.1038/mtna.2013.66.

24.

Low mercury levels in marine fish from estuarine and coastal environments in southern China.

Pan K, Chan H, Tam YK, Wang WX.

Environ Pollut. 2014 Feb;185:250-7. doi: 10.1016/j.envpol.2013.11.004. Epub 2013 Nov 28.

PMID:
24292441
25.

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.

Maier MA, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, Tam YK, Ansell SM, Kumar V, Qin J, Zhang X, Wang Q, Panesar S, Hutabarat R, Carioto M, Hettinger J, Kandasamy P, Butler D, Rajeev KG, Pang B, Charisse K, Fitzgerald K, Mui BL, Du X, Cullis P, Madden TD, Hope MJ, Manoharan M, Akinc A.

Mol Ther. 2013 Aug;21(8):1570-8. doi: 10.1038/mt.2013.124. Epub 2013 Jun 25.

26.

Response of bacterioplankton to a glucose gradient in the absence of lysis and grazing.

Zhang R, Weinbauer MG, Tam YK, Qian PY.

FEMS Microbiol Ecol. 2013 Sep;85(3):443-51. doi: 10.1111/1574-6941.12133. Epub 2013 May 1.

27.

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.

Belliveau NM, Huft J, Lin PJ, Chen S, Leung AK, Leaver TJ, Wild AW, Lee JB, Taylor RJ, Tam YK, Hansen CL, Cullis PR.

Mol Ther Nucleic Acids. 2012 Aug 14;1:e37. doi: 10.1038/mtna.2012.28.

28.

Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.

Tam YY, Chen S, Zaifman J, Tam YK, Lin PJ, Ansell S, Roberge M, Ciufolini MA, Cullis PR.

Nanomedicine. 2013 Jul;9(5):665-74. doi: 10.1016/j.nano.2012.11.006. Epub 2012 Dec 6.

PMID:
23219877
29.

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, Butler D, Eltepu L, Matsuda S, Narayanannair JK, Rajeev KG, Hafez IM, Akinc A, Maier MA, Tracy MA, Cullis PR, Madden TD, Manoharan M, Hope MJ.

Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33. doi: 10.1002/anie.201203263. Epub 2012 Jul 10.

31.

Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.

Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, Lin PJ, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR.

Int J Cancer. 2012 Sep 1;131(5):E781-90. doi: 10.1002/ijc.27361. Epub 2012 Jan 3.

32.

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.

Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR.

Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4.

33.

Rational design of cationic lipids for siRNA delivery.

Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ.

Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17.

PMID:
20081866
34.

Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.

Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD, Cullis PR, Dutz JP, Tam YK.

Int Immunol. 2009 Jul;21(7):757-67. doi: 10.1093/intimm/dxp044. Epub 2009 Jun 5.

PMID:
19502586
35.

Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.

Wilson KD, Tam YK.

Expert Rev Clin Pharmacol. 2009 Mar;2(2):181-93. doi: 10.1586/17512433.2.2.181.

PMID:
24410650
36.

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.

Wilson KD, de Jong SD, Tam YK.

Adv Drug Deliv Rev. 2009 Mar 28;61(3):233-42. doi: 10.1016/j.addr.2008.12.014. Epub 2009 Feb 13. Review.

PMID:
19232375
37.

The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine.

Wilson KD, de Jong SD, Kazem M, Lall R, Hope MJ, Cullis PR, Tam YK.

J Gene Med. 2009 Jan;11(1):14-25. doi: 10.1002/jgm.1267.

PMID:
19003796
38.

Molecular Differentiation of Fusarium solani f. sp. glycines from Other F. solani Based on Mitochondrial Small Subunit rDNA Sequences.

Li S, Tam YK, Hartman GL.

Phytopathology. 2000 May;90(5):491-7. doi: 10.1094/PHYTO.2000.90.5.491.

39.

The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN.

Raney SG, Wilson KD, Sekirov L, Chikh G, de Jong SD, Cullis PR, Tam YK.

J Drug Target. 2008 Aug;16(7):564-77. doi: 10.1080/10611860802228756.

PMID:
18686126
40.

Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma Chuanxiong, in the rat.

Yan R, Ko NL, Li SL, Tam YK, Lin G.

Drug Metab Dispos. 2008 Feb;36(2):400-8. Epub 2007 Nov 26.

PMID:
18039808
41.

Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.

Wilson KD, Raney SG, Sekirov L, Chikh G, deJong SD, Cullis PR, Tam YK.

Int Immunopharmacol. 2007 Aug;7(8):1064-75. Epub 2007 May 2.

PMID:
17570323
42.
44.
45.

Effect of protein and calorie malnutrition on drug metabolism in rat - in vitro.

Mao ZL, Tam YK, Coutts RT.

J Pharm Pharm Sci. 2006;9(1):60-70.

46.

Protocatechuic acid induces cell death in HepG2 hepatocellular carcinoma cells through a c-Jun N-terminal kinase-dependent mechanism.

Yip EC, Chan AS, Pang H, Tam YK, Wong YH.

Cell Biol Toxicol. 2006 Jul;22(4):293-302. Erratum in: Cell Biol Toxicol. 2007 Mar;23(2):139.

PMID:
16835731
48.

Supplemental Content

Loading ...
Support Center